Literature DB >> 35460492

Patients on Buprenorphine Formulations Undergoing Surgery.

Katelynn Champagne1, Preshita Date1, Juan Pablo Forero2, Joshua Arany3, Karina Gritsenko4,5.   

Abstract

PURPOSE OF REVIEW: To review the pharmacology of buprenorphine, the evolution of buprenorphine dosing recommendations, and the current literature regarding its recommendations for the perioperative period. RECENT
FINDINGS: There is a consensus that for all surgeries, buprenorphine should be continued throughout the perioperative period. If the surgery is a minimal to mild pain surgery, no dose adjustment is needed. There is no clear consensus regarding moderate to severe pain. With all surgeries, multimodal analgesia should be utilized, with regional anesthesia when possible. Patients taking buprenorphine should continue their buprenorphine perioperatively; whether to decrease or maintain dosing is up for debate. Multimodal analgesia should also be used throughout the perioperative period, and communication between the patient and all provider teams is of the utmost importance to provide adequate analgesia during the perioperative period, as well as to arrange safe analgesia upon discharge.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Buprenorphine; Buprenorphine pharmacology; Multimodal analgesia; Perioperative buprenorphine; Pre-operative buprenorphine, Post-operative buprenorphine

Mesh:

Substances:

Year:  2022        PMID: 35460492     DOI: 10.1007/s11916-022-01046-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  34 in total

Review 1.  Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

Authors:  Marion A Coe; Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2019 Mar/Apr       Impact factor: 3.702

Review 2.  Buprenorphine-naloxone therapy in pain management.

Authors:  Kelly Yan Chen; Lucy Chen; Jianren Mao
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

3.  Clinical pharmacology of buprenorphine: ceiling effects at high doses.

Authors:  S L Walsh; K L Preston; M L Stitzer; E J Cone; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  1994-05       Impact factor: 6.875

4.  Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs.

Authors:  Donna A Volpe; Grainne A McMahon Tobin; R Daniel Mellon; Aspandiar G Katki; Robert J Parker; Thomas Colatsky; Timothy J Kropp; S Leigh Verbois
Journal:  Regul Toxicol Pharmacol       Date:  2011-01-06       Impact factor: 3.271

Review 5.  Buprenorphine use: the international experience.

Authors:  Maria Patrizia Carrieri; Leslie Amass; Gregory M Lucas; David Vlahov; Alex Wodak; George E Woody
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

Review 6.  Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel.

Authors:  Lynn Kohan; Sudheer Potru; Antje M Barreveld; Michael Sprintz; Olabisi Lane; Anuj Aryal; Trent Emerick; Anna Dopp; Sophia Chhay; Eugene Viscusi
Journal:  Reg Anesth Pain Med       Date:  2021-08-12       Impact factor: 6.288

Review 7.  To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.

Authors:  T Anthony Anderson; Aurora N A Quaye; E Nalan Ward; Timothy E Wilens; Paul E Hilliard; Chad M Brummett
Journal:  Anesthesiology       Date:  2017-06       Impact factor: 7.892

8.  Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.

Authors:  Jordan F Karp; Meryl A Butters; Amy E Begley; Mark D Miller; Eric J Lenze; Daniel M Blumberger; Benoit H Mulsant; Charles F Reynolds
Journal:  J Clin Psychiatry       Date:  2014-08       Impact factor: 4.384

9.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

Review 10.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.

Authors:  Jeffrey Gudin; Jeffrey Fudin
Journal:  Pain Ther       Date:  2020-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.